Govindan R, et al. Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRAS G12Cinhibitor, evaluated in NSCLC. Abstract OA02.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
Niet standaard oxaliplatin bij ouderen met stadium III-dikkedarmkanker
jan 2017 | Maag-darm-leveroncologie